|
Contact
|
Newsletter
|
Sitemap
|
Deutsch
»
Bayer Group
Home
Subgroups
Bayer AG (Holding Company)
Bayer HealthCare
Bayer CropScience
Bayer MaterialScience
Bayer Business Services
Bayer Technology Services
Currenta
Topics
Business & Finance
Research & Innovation
Products
Responsible Care
Social Responsibility
Bayer People
Europe
North America
Asia & Pacific
Central-/Latin America
Africa & Middle East
Press Contact
Bayer AG
(Holding Company)
Bayer HealthCare
Bayer CropScience
Bayer MaterialScience
Bayer Business Services
Bayer Technology Services
Photo-Service
Biographies
Board of Management
Subgroup Management Boards
Supervisory Board
Speeches
Photos
Bayer AG (Holding Company)
Bayer HealthCare
Bayer CropScience
Bayer MaterialScience
Bayer Business Services
Bayer Technology Services
Currenta
Education and Training
Research
Locations
Environmental Protection
BayKomm
TV Service
Bayer AG (Holding Company)
Bayer HealthCare
Bayer CropScience
Bayer MaterialScience
Bayer Business Services
Bayer Technology Services
Currenta
Bayer Links
Bayer Global
Bayer HealthCare
Bayer CropScience
Bayer MaterialScience
Bayer Business Services
Bayer Technology Services
Currenta
Special Interest
Investor Relations
Jobs and Career
Foundations
Sports
Culture
Subgroups
Bayer AG (Holding Company)
|
1 - 20
|
21 - 38
|
|
Tuesday - February 21, 2012
Bayer initiates global “Bee Care Program” to further promote bee health
“Bayer Bee Care Centers” to open in Europe and the USA
» more
Friday - January 27, 2012
“Sustainability Yearbook 2012” listing globally top performers presented in Davos:
Bayer rated the most sustainable German company in its sector
One of just three chemical companies worldwide to receive Gold Class seal of quality from rating agency SAM
» more
Tuesday - December 20, 2011
Not intended for U.S. and UK media: Clear commitment to innovation
Bayer: Four potential blockbusters in the Pharma pipeline
Good prospects for Xarelto™, VEGF Trap-Eye, Alpharadin and regorafenib / Market launches in the next 18 months planned / Research and development budget for 2012 approximately EUR 3 billion again
» more
Monday - December 19, 2011
Employees donate over EUR 300,000 and company contributes a further EUR 400,000:
Bayer foundation provides EUR 700,000 for construction of children care facility in Japanese earthquake area
Home for orphans in Tohoku region / Bayer’s relief aid to Japan totals almost EUR 2.3 million
» more
Monday - December 19, 2011
Awards from the Bayer Science & Education Foundation:
Bayer Early Excellence in Science Award 2011: EUR 30,000 for young research scientists
Dr. Cristobal Uauy (John Innes Centre in Norwich, Great Britain) wins the „Biology“ category / Dr. Andreas Bender (University of Cambridge, Great Britain) takes the „Chemistry“ award / Prof. Dr. Arne Thomas (Technical University Berlin) awarded prize in the „Materials“ field
» more
Thursday - November 17, 2011
New edition of research, the Bayer scientific magazine
Innovations from the world of research at Bayer
Personalized medicine against cancer / Creating new active crop protection ingredients with biotechnology / Electric mobility: materials for the cars of the future
» more
Wednesday - November 16, 2011
International Press Conference
„Perspective on Growth in Asia“
» more
Wednesday - November 16, 2011
“Perspective on Growth in Asia”
Bayer plans further expansion in Asia
Sales in the region to grow to well over EUR 11 billion by 2015 / Some EUR 6 billion in sales expected in Greater China alone / Plans to expand production, distribution network and research / Further capital expenditures of EUR 1.8 billion in Asia by 2015 / New TDI production facility dedicated in Shanghai
» more
Friday - November 4, 2011
Not intended for U.S. and UK Media - Stroke Prevention in Patients with Atrial Fibrillation:
US FDA Approves Bayer’s Xarelto® (Rivaroxaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation
Rivaroxaban is highly effective and well tolerated in protecting patients with Atrial Fibrillation from stroke / Rivaroxaban is the only anticoagulant with once-daily fixed dosing for stroke prevention in patients with atrial fibrillation / Rivaroxaban does not require routine coagulation monitoring, making it more convenient to both patients and physicians
» more
Thursday - October 27, 2011
Bayer AG Third Quarter 2011 Results and News Conference Call
» more
Thursday - October 27, 2011
After a good third quarter: Bayer confirms Group outlook
Sales up by 4.8 percent (adjusted) to EUR 8,670 million / Continuing growth momentum in the emerging markets (adjusted: plus 9.5 percent) / Operating result (EBIT) increased by 94.9 percent to EUR 1,099 million / EBITDA before special items up by 8.5 percent to EUR 1,805 million / HealthCare and CropScience margins distinctly improved – MaterialScience weaker / Net income more than doubled to EUR 642 million (plus 125.3 percent)
» more
Friday - October 21, 2011
Award for innovative environmental projects:
Bayer honors four young environmentalists from Indonesia, Ecuador, Kenya and the Philippines
» more
Monday - October 17, 2011
Environmental protection at first-hand:
Ambassadors in the service of the environment visit Bayer
Around 50 young people from Africa, Asia and Latin America participate in a week-long study trip on the environment / The program is part of the partnership between Bayer and the United Nations Environment Programme (UNEP)
» more
Wednesday - October 5, 2011
Global youth environment summit in Bandung:
Bayer and UNEP honor winners of International Children's Painting Competition on the Environment
13-year-old winner from the Philippines urges global community to increase environmental protection efforts / 4 million pictures from 99 countries / Launch of the new painting competition with the theme: “Green Communities” / UNEP boss Steiner: “Responsible young people are the United Nations' most valuable asset”
» more
Media resources
Wednesday - October 5, 2011
Centennial of Bayer's Japanese company
Bayer plans continued growth in Japan
Positive development despite earthquake and tsunami / Sales to grow by an average 6 percent annually through 2015 / Donation of EUR 700,000 for long-term reconstruction project in the earthquake zone / Bayer's relief aid totals nearly EUR 2.3 million
» more
Friday - September 30, 2011
Ad-hoc-Announcement according to § 15 WpHG
Bayer AG: Phase III Study of Bayer’s Rivaroxaban in Patients with Acute Coronary Syndrome Meets Primary Efficacy Endpoint
» more
Friday - September 16, 2011
Bayer Science & Education Foundation:
EUR 200,000 for scholarships and teacher training
Promotion of ambitious study projects and international work experience / Emphasis on natural sciences and medicine / Hermann Strenger scholarships for career training / About EUR 938,000 already provided to support 177 young people since 2007
» more
Wednesday - September 14, 2011
Renewed inclusion in the Carbon Leadership indices:
Bayer is still a world leader in climate protection
Recognition of transparent reporting and contributions to reducing CO2 / Indices offer guidance for sustainable investment
» more
Friday - September 9, 2011
Renewed inclusion in Dow Jones Sustainability Indices:
Bayer remains “best in class” in sustainability
Indices provide sustainable investors with a guide
» more
Monday - August 8, 2011
Famine in East Africa: Bayer provides immediate aid
EUR 100,000 donated to the U.N. World Food Programme
» more
|
1 - 20
|
21 - 38
|
|
Copyright @ Bayer AG
General Conditions of Use
-
Privacy Statement
-
Imprint
Print page
Search
Advanced Search
Publications
Stockholders' Newsletter
Sustainable Development Report
Annual Report
Publications Overview
Newsletter
We will keep you informed about the latest news.
Events
Tuesday, February 28, 2012
Financial News Conference Full Year 2011
Contact:
Günter Forneck
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Your selection:
0
Download(s)